SCHEMBL6162908

SCHEMBL6162908

CCC(=O)C(O)CO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14519909 1.00
Levulinic Acid SCHEMBL31473190 0.81 LMNA (0.54)
SCHEMBL27593847 0.79 CA1 (0.36)
SCHEMBL108041 0.79
SCHEMBL10141472 0.79
SCHEMBL15196065 0.79
SCHEMBL28276115 0.78
Water SCHEMBL28805570 0.77
Hydrochloric Acid SCHEMBL30373831 0.77
SCHEMBL439347 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0939632-B1 NON-PEPTIDYL VASOPRESSIN V1a ANTAGONISTS LILLY CO ELI (US) 2005-10-05 EP claimed
US-6521611-B2 2-(azetidin-2-on-1-yl) acetic acid derivatives; treatment of obsessive-compulsive disorder ELI LILLY AND COMPANY 2003-02-18 US claimed
US-20130059807-A1 BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS SATIOGEN PHARMACEUTICALS, INC. (US) 2013-03-07 US disclosed
US-20130034536-A1 Bile Acid Recycling Inhibitors for Treatment of Pancreatitis Lumena Pharmaceuticals, Inc. (US) 2013-02-07 US disclosed
US-20120165309-A1 HETERO RING DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-28 US disclosed
US-20120157399-A1 BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF OBESITY AND DIABETES SATIOGEN PHARMACEUTICALS, INC. (US) 2012-06-21 US disclosed
US-20100267707-A1 Tyrosine Kinase Inhibitors MERCK SHARP & DOHME CORP. (US) 2010-10-21 US disclosed
US-20100130472-A1 BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF OBESITY AND DIABETES SATIOGEN PHARMACEUTICALS, INC. (US) 2010-05-27 US disclosed
EP-0939632-B1 NON-PEPTIDYL VASOPRESSIN V1a ANTAGONISTS LILLY CO ELI (US) 2005-10-05 EP disclosed
US-6610680-B1 Administering as adjuncts in heart failure or as antithrombotic agents, treatment of obsessive-compulsive disorder, aggressive disorders, depression and anxiety ELI LILLY AND COMPANY 2003-08-26 US disclosed
US-6521611-B2 2-(azetidin-2-on-1-yl) acetic acid derivatives; treatment of obsessive-compulsive disorder ELI LILLY AND COMPANY 2003-02-18 US disclosed
EP-0939632-A4 NON-PEPTIDYL VASOPRESSIN V1a ANTAGONISTS LILLY CO ELI (US) 2002-09-25 EP disclosed
US-20020049187-A1 Non-peptidyl vasopressin V1a antagonists BRUNS ROBERT F (US) 2002-04-25 US disclosed
US-6204260-B1 2-(AZETIDIN-2-ON-1-YL)ACETIC ACID DERIVATIVES ELI LILLY AND COMPANY 2001-03-20 US disclosed
EP-0939632-A1 NON-PEPTIDYL VASOPRESSIN V1a ANTAGONISTS ELI LILLY AND COMPANY (US) 1999-09-08 EP disclosed
WO-1997030707-A1 NON-PEPTIDYL VASOPRESSIN V1a ANTAGONISTS ELI LILLY AND COMPANY (US) 1997-08-28 WO disclosed